New FDA Approved Eye Drops May Improve Near Vision


December 14, 2021 – A new FDA-approved eye drug could replace reading glasses for millions of Americans with age-related blurry vision.

The product, called Vuity, was approved by the FDA in October and hit the market last week. The new medicine begins to work in about 15 minutes and provides clearer vision for 6 to 10 hours.

Vuity is the first eye drops approved by the FDA to treat the condition known as presbyopia, which tends to affect people aged 40 and over. The prescription drug uses the eye’s natural ability to reduce the size of its pupil.

“Reducing the pupil size increases the depth of field or depth of field, and it allows you to naturally focus on different ranges,” George Waring, MD, principal investigator of the clinical trial told CBS News. .

For people who use the drops, it can be difficult to adjust their focus between objects at first. During the clinical trial, the drops had mild side effects such as headache and red eyes.

“This is something that we believe will be well tolerated in the long term, but it will be formally evaluated and studied,” Waring said.

Presbyopia can be diagnosed with a basic eye exam performed by an ophthalmologist, according to a press release from Allergan, which manufactures the drops. It is a common and progressive eye condition that affects 128 million Americans.

In the clinical trial, 750 presbyopic participants tested the drops, and a “statistically significant proportion” were able to read three or more additional lines on a reading chart, Allergan said.

The drops are intended for mild to intermediate cases of presbyopia and should not be used for driving at night or doing activities in low light conditions. The drops will also not help people with other eye conditions, such as nearsightedness (nearsightedness) and farsightedness (hyperopia).

The drops work best for 40-55 year olds and are less effective after 65 years.

A 30-day supply costs around $ 80 and is not covered by insurance, CBS News reported.


Comments are closed.